Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.

Abstract	The second Key Point for Decision Makers, which reads.
Authors	D Lee, A Amadi, J Sabater, J Ellis, H Johnson, S Kotapati, S McNamara, A Walker, M Cooper, K Patterson, N Roskell, Y Meng
Journal	PharmacoEconomics - open (Pharmacoecon Open) Vol. 3 Issue 1 Pg. 127 (03 2019) ISSN: 2509-4254 [Electronic] Switzerland
PMID	30206825 (Publication Type: Journal Article, Published Erratum)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!